Thus, more than in appetite suppression, the anti-obesity properties of CB1 antagonists and inverse agonists should be sought in their ability to stimulate lipolysis, energy dissipation, and fatty acid oxidation by halting endocannabinoid signals that promote energy storage in the adipose and other organs [39,47]. The gene discussed is CNR1; the disease is obesity disorder.